# Depixus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/depixus

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.depixus.com
- Total disclosed funding: $22M
- Latest round: Series A (Apr 9, 2021)
- Investors on record: 3

## About

Depixus SAS specializes in advanced biomolecular analysis, leveraging cutting-edge technology to visualize molecular interactions and provide researchers with detailed insights into molecular dynamics.Founded in 2012 and headquartered in Paris, France, Depixus SAS focuses on biomolecular analysis. The company raised EUR 18.50 mn in its Series A funding round on April 9, 2021, led by Lansdowne Partners, with participation from Arix Bioscience and Casdin Capital. The firm has completed one deal to date, raising a total of EUR 18.50 mn, with a current company valuation of EUR 50.99 mn.Depixus specializes in advanced biomolecular analysis through its flagship product, the MAGNA One, which employs magnetic force spectroscopy (MFS) to visualize molecular interactions in real-time. This platform allows researchers to observe thousands of individual biomolecular interactions, significantly enhancing insights into molecular dynamics and heterogeneity. Depixus caters to a diverse clientele, including academic institutions and biotechnology companies across Europe and North America.Depixus generates revenue primarily through the sale and installation of its MAGNA One instruments and associated services. Revenue streams include direct sales to research institutions, maintenance agreements, and subscription-based access to software tools. The pricing for the MAGNA One reflects the complexity of the technology, positioning Depixus in a specialized market focused on biomolecular research.In April 2021, Depixus SAS secured EUR 18.50 mn in Series A funding, which will be utilized to develop its proprietary MAGNA™ instrument system, workflows, and reagents toward commercial launch. The company is strategically planning to expand its operational reach into new markets and geographic regions, although specific details on these expansions have yet to be disclosed.

## Funding rounds

- Series A, Apr 9, 2021, $22M — Casdin Capital, Lansdowne Partners, Arix Bioscience

## Investors

- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- Lansdowne Partners (https://capitalatlas.ai/funds/lansdowne-partners) — Series A
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series A